Philips, Celsion advance MR-guided HIFU collaboration

Jonathan Batchelor | | Health Imaging | Oncology Imaging
Royal Philips Electronics and Celsion said that their joint research program to evaluate Celsion's heat-activated liposomal drug ThermoDox in combination with MR-guided high-intensity focused ultrasound (HIFU) as a combination therapy to non-invasively treat difficult cancers has successfully completed the feasibility stage.

The program has now moved into pre-clinical development and will focus on the combined use of ThermoDoxand Philips’ MR-HIFU system for the treatment of pancreatic cancer and cancer metastases in bone.

Philips said its MR-HIFU system has the potential to precisely and non-invasively target lesions with acoustic energy, creating sufficient heat to activate ThermoDox and preferentially release high concentrations of the drug doxorubicin. The firms hope this Celsion-Philips combinational treatment approach may change the paradigm for addressing a broad range of cancers.

For bone metastases, ThermoDox combined with MR-HIFU will be investigated both for tumor control as well as for palliative pain treatment. For pancreatic cancer, ThermoDox combined with MR-HIFU will be investigated for tumor control.

Jonathan Batchelor

Related Content

MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive
Breast cancer rates are on the rise, new report reveals

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.